KR20240043789A - 아토피성 피부염의 치료 - Google Patents

아토피성 피부염의 치료 Download PDF

Info

Publication number
KR20240043789A
KR20240043789A KR1020247007705A KR20247007705A KR20240043789A KR 20240043789 A KR20240043789 A KR 20240043789A KR 1020247007705 A KR1020247007705 A KR 1020247007705A KR 20247007705 A KR20247007705 A KR 20247007705A KR 20240043789 A KR20240043789 A KR 20240043789A
Authority
KR
South Korea
Prior art keywords
injection
antibody
fragment
score
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247007705A
Other languages
English (en)
Korean (ko)
Inventor
벤 포터-브라운
소니아 콰라티노
리처드 씨 에이 세인슨
존 파웰
Original Assignee
키맵 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2115152.7A external-priority patent/GB202115152D0/en
Priority claimed from GBGB2204211.3A external-priority patent/GB202204211D0/en
Priority claimed from GBGB2204291.5A external-priority patent/GB202204291D0/en
Application filed by 키맵 리미티드 filed Critical 키맵 리미티드
Publication of KR20240043789A publication Critical patent/KR20240043789A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020247007705A 2021-08-10 2022-08-09 아토피성 피부염의 치료 Pending KR20240043789A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB202111492 2021-08-10
GB2111492.1 2021-08-10
GBGB2115152.7A GB202115152D0 (en) 2021-10-21 2021-10-21 Treatment of atopic dermatitis
GB2115152.7 2021-10-21
GB2204211.3 2022-03-24
GBGB2204211.3A GB202204211D0 (en) 2022-03-24 2022-03-24 Treatment of atopic dermatitis
GB2204291.5 2022-03-25
GBGB2204291.5A GB202204291D0 (en) 2022-03-25 2022-03-25 Treatment of atopic dermatitis
PCT/GB2022/052070 WO2023017252A1 (en) 2021-08-10 2022-08-09 Treatment of atopic dermatitis

Publications (1)

Publication Number Publication Date
KR20240043789A true KR20240043789A (ko) 2024-04-03

Family

ID=82942548

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247007705A Pending KR20240043789A (ko) 2021-08-10 2022-08-09 아토피성 피부염의 치료

Country Status (11)

Country Link
US (2) US20230235069A1 (https=)
EP (1) EP4384270A1 (https=)
JP (1) JP2024530954A (https=)
KR (1) KR20240043789A (https=)
AR (1) AR126749A1 (https=)
AU (1) AU2022326849A1 (https=)
CA (1) CA3228708A1 (https=)
IL (1) IL310701A (https=)
MX (1) MX2024001877A (https=)
TW (1) TW202330023A (https=)
WO (1) WO2023017252A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260026080A (ko) * 2023-06-20 2026-02-25 키맵 리미티드 면역 매개 질환의 투여 및 치료와 면역 매개 질환과 관련된 바이오마커
WO2025090570A1 (en) * 2023-10-23 2025-05-01 Abcellera Biologics Inc. Anti-ox40l antibodies and methods of use
WO2025233445A1 (en) * 2024-05-08 2025-11-13 Kymab Limited Treatment of head and neck atopic dermatitis
WO2025255353A1 (en) * 2024-06-06 2025-12-11 Apogee Therapeutics, Inc. Dosage and administration of an anti-ox40l antibody

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2426744C2 (ru) * 2005-12-16 2011-08-20 Дженентек, Инк. Антитела к ox40l и способы их применения
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP2513145B1 (en) * 2009-12-14 2018-01-24 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN107074951B (zh) * 2014-08-04 2021-08-03 贝勒研究院 拮抗性抗-ox40l抗体及其使用方法
MX2017011194A (es) 2015-03-03 2018-04-10 Kymab Ltd Anticuerpos, usos y métodos.
US9512229B2 (en) * 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods

Also Published As

Publication number Publication date
EP4384270A1 (en) 2024-06-19
US20230235069A1 (en) 2023-07-27
AR126749A1 (es) 2023-11-08
TW202330023A (zh) 2023-08-01
MX2024001877A (es) 2024-02-28
JP2024530954A (ja) 2024-08-27
WO2023017252A1 (en) 2023-02-16
IL310701A (en) 2024-04-01
US20250353918A1 (en) 2025-11-20
AU2022326849A1 (en) 2024-03-21
CA3228708A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
US12465635B2 (en) Methods of treating inflammatory arthritis using secukinumab
KR20240043789A (ko) 아토피성 피부염의 치료
JP2025106377A (ja) Ｉｌ－１７アンタゴニストを用いて化膿性汗腺炎を治療すること
US20250026858A1 (en) Methods of treating chronic spontaneous urticaria using ligelizumab
CA3229249A1 (en) Treatment of chronic obstructive pulmonary disease with an anti-interleukin-33 antibody
JP2024535831A (ja) 結節性痒疹の治療のためのｉｌ－１３阻害剤
CN118488851A (zh) 特应性皮炎的治疗
RU2783540C2 (ru) Способы лечения хронической спонтанной крапивницы с применением лигелизумаба
KR20220110512A (ko) 인터류킨-17(il-17) 길항제를 사용하여 편평 태선을 치료하는 방법
HK40035240B (en) Methods of treating psoriatic arthritis using il-17 antagonists
HK40061520A (en) Pharmaceutical compositions comprising secukinumab
HK1229257B (en) Methods of treating ankylosing spondylitis using anti-il-17 antibodies

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000